Starting Dose of Adderall for ADHD
For adults with ADHD, start Adderall at 5 mg twice daily (10 mg/day total), with titration based on clinical response. 1
Age-Specific Dosing Recommendations
Adults (≥18 years)
The evidence consistently supports a low starting dose approach for adults:
- Initial dose: 5 mg twice daily (10 mg/day total) 2
- Titrate gradually according to clinical response
- Mean effective doses in clinical trials ranged from 10.77 mg/day to 80 mg/day, depending on formulation and individual response 2, 3
Extended-release formulations offer alternative dosing:
- MAS XR (Adderall XR): Start at 20 mg once daily, with dose escalation to 40-60 mg/day as needed 3, 4
- Triple-bead MAS (SHP465): Start at 12.5 mg once daily, with titration up to 75 mg/day 5, 6
The research demonstrates that approximately 54% of adults respond positively to low-dose immediate-release Adderall, with mean effective doses around 10.77 mg/day (0.14 mg/kg/day) 2. Higher doses may be needed for patients with severe symptoms (ADHD Rating Scale score >32), where 60 mg/day showed superior efficacy 3.
Children and Adolescents (6-17 years)
For pediatric patients:
- Starting dose: 12.5 mg once daily (extended-release formulation)
- Titrate to 12.5-25 mg/day based on response 7
Preschool-Aged Children (4-5 years)
Critical caveat: Amphetamines are metabolized more slowly in preschool-aged children 8. If medication is deemed necessary (only for moderate-to-severe dysfunction unresponsive to behavioral therapy):
- Start with very low doses
- Increase in smaller increments than older children
- Maximum doses have not been adequately studied in this age group 8
Clinical Decision Algorithm
Step 1: Assess severity and comorbidities
- Severe symptoms (ADHD-RS-IV >32): Consider higher target doses (40-60 mg/day) 3
- Comorbid anxiety disorders: Use caution—Adderall precipitated acute anxiety in 57% (4/7) of patients with pre-existing anxiety 2
- Comorbid substance use disorder: Consider non-stimulant alternatives first 8
Step 2: Choose formulation based on coverage needs
- Immediate-release: 3-hour peak, requires twice-daily dosing 1
- Extended-release (MAS XR): 12-hour duration of action 3
- Triple-bead formulation (SHP465): Up to 16-hour duration 5
Step 3: Titration schedule
- Start low (5 mg BID for immediate-release or 20 mg daily for extended-release)
- Assess response weekly
- Increase by 5-10 mg increments for immediate-release or 20 mg increments for extended-release
- Target the minimum effective dose that controls symptoms
Step 4: Monitor for response and adverse effects
- Efficacy markers: Improvement in ADHD Rating Scale scores within the first week of treatment 3
- Safety monitoring: Height, weight, pulse, blood pressure 9
- Common adverse effects: Decreased appetite (32%), insomnia (32%), dry mouth (43%), headache (30%) 4
Important Caveats
Diversion risk in adolescents: Monitor prescription refill patterns and consider extended-release formulations to minimize abuse potential 8. Adolescents require special attention to medication coverage during driving hours due to increased crash risk 8.
Cardiovascular monitoring: While mean increases in pulse (3.5-5.7 bpm) and systolic blood pressure (0.3-3.8 mmHg) are modest 6, 7, baseline cardiovascular assessment is essential given amphetamines' sympathomimetic effects 1.
Duration of effect considerations: For adults needing symptom control throughout the day (including evening activities or driving), longer-acting formulations or late-afternoon short-acting doses may be necessary 8, 3.
Non-responders: Approximately 38% of adults do not respond adequately to Adderall 2. If no benefit occurs after adequate trial (appropriate dose and duration), switch to lisdexamfetamine before trying non-stimulants 9.